vilazodone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
4223 163521-12-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vilazodone
  • viibryd
  • vilazodone hydrochloride
  • vilazodone HCl
A benzofuran, indole, and piperazine derivative that functions as a SEROTONIN UPTAKE INHIBITOR and partial SEROTONIN 5-HT1 RECEPTOR AGONIST. It is used as an ANTIDEPRESSIVE AGENT.
  • Molecular weight: 441.54
  • Formula: C26H27N5O2
  • CLOGP: 4.33
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 102.29
  • ALOGS: -3.56
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 4.85 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.76 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.03 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 15.66 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 21, 2011 FDA FOREST LABS LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 255.28 20.04 122 5843 62299 63420758
Abnormal dreams 143.47 20.04 49 5916 10467 63472590
Hallucination 123.44 20.04 72 5893 54745 63428312
Persistent genital arousal disorder 99.18 20.04 18 5947 268 63482789
Anxiety 94.56 20.04 109 5856 217432 63265625
Serotonin syndrome 90.23 20.04 47 5918 28635 63454422
Agitation 80.95 20.04 57 5908 59700 63423357
Nightmare 76.70 20.04 37 5928 19157 63463900
Sleep paralysis 72.93 20.04 16 5949 644 63482413
Mania 68.77 20.04 30 5935 12337 63470720
Paraesthesia 62.04 20.04 75 5890 156891 63326166
Completed suicide 56.57 20.04 69 5896 145604 63337453
Insomnia 56.18 20.04 84 5881 215168 63267889
Anger 55.84 20.04 26 5939 12430 63470627
Crying 50.73 20.04 30 5935 23313 63459744
Suicide attempt 47.54 20.04 42 5923 60876 63422181
Tremor 47.10 20.04 60 5905 132179 63350878
Irritability 47.04 20.04 32 5933 31662 63451395
Feeling abnormal 46.16 20.04 63 5902 148329 63334728
Seizure 42.29 20.04 57 5908 132577 63350480
Dizziness 42.02 20.04 111 5854 429814 63053243
Depression 41.98 20.04 70 5895 196422 63286635
Tardive dyskinesia 35.81 20.04 17 5948 8485 63474572
Withdrawal syndrome 34.04 20.04 22 5943 19975 63463082
Muscle twitching 31.92 20.04 21 5944 19647 63463410
Dissociation 29.89 20.04 11 5954 2908 63480149
Electric shock sensation 29.54 20.04 8 5957 780 63482277
Panic attack 29.50 20.04 21 5944 22310 63460747
Nausea 25.10 20.04 151 5814 854320 62628737
Obsessive-compulsive disorder 23.05 20.04 10 5955 4050 63479007
Hypnagogic hallucination 22.97 20.04 5 5960 194 63482863
Diarrhoea 22.64 20.04 129 5836 715237 62767820
Homeless 21.17 20.04 4 5961 75 63482982

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 142.18 33.14 61 1928 40327 34914615
Serotonin syndrome 141.05 33.14 50 1939 19883 34935059
Completed suicide 91.20 33.14 61 1928 98107 34856835
Mania 52.83 33.14 20 1969 9491 34945451
Sexual dysfunction 49.03 33.14 17 1972 6286 34948656
Anxiety 40.30 33.14 38 1951 99390 34855552
Overdose 35.36 33.14 34 1955 91025 34863917
Irritability 34.61 33.14 20 1969 24670 34930272

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Suicidal ideation 213.97 21.28 105 5475 76235 79662573
Serotonin syndrome 138.28 21.28 66 5514 44961 79693847
Completed suicide 125.44 21.28 117 5463 245650 79493158
Persistent genital arousal disorder 98.00 21.28 17 5563 264 79738544
Abnormal dreams 94.44 21.28 34 5546 11378 79727430
Anxiety 85.96 21.28 96 5484 248416 79490392
Hallucination 66.48 21.28 52 5528 85693 79653115
Mania 66.04 21.28 30 5550 18230 79720578
Anger 58.31 21.28 27 5553 17135 79721673
Irritability 55.40 21.28 35 5545 41109 79697699
Sleep paralysis 55.19 21.28 12 5568 626 79738182
Nightmare 53.33 21.28 29 5551 25832 79712976
Tremor 50.81 21.28 61 5519 170022 79568786
Crying 50.76 21.28 27 5553 23016 79715792
Insomnia 50.15 21.28 73 5507 245097 79493711
Paraesthesia 45.86 21.28 59 5521 176264 79562544
Agitation 44.13 21.28 44 5536 99671 79639137
Suicide attempt 37.43 21.28 37 5543 82895 79655913
Intentional overdose 36.63 21.28 41 5539 105919 79632889
Muscle twitching 33.16 21.28 21 5559 24743 79714065
Depression 32.46 21.28 56 5524 216734 79522074
Feeling abnormal 30.48 21.28 46 5534 159153 79579655
Tardive dyskinesia 27.92 21.28 14 5566 10557 79728251
Dizziness 27.49 21.28 90 5490 526351 79212457
Off label use 27.07 21.28 130 5450 907085 78831723
Dissociation 26.00 21.28 10 5570 4011 79734797
Memory impairment 25.35 21.28 35 5545 111699 79627109
Withdrawal syndrome 24.58 21.28 18 5562 26836 79711972
Product substitution issue 24.22 21.28 16 5564 20240 79718568
Seizure 23.45 21.28 45 5535 188789 79550019
Obsessive-compulsive disorder 22.25 21.28 10 5570 5917 79732891
Panic attack 21.64 21.28 16 5564 24200 79714608

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N06AX24 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTIDEPRESSANTS
Other antidepressants
MeSH PA D000928 Antidepressive Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D014179 Neurotransmitter Uptake Inhibitors
MeSH PA D011619 Psychotropic Drugs
MeSH PA D017367 Selective Serotonin Reuptake Inhibitors
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D018490 Serotonin Agents
MeSH PA D017366 Serotonin Receptor Agonists
CHEBI has role CHEBI:35469 antidepressants
CHEBI has role CHEBI:35941 serotonin agonists
CHEBI has role CHEBI:50949 SSRI

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Major depressive disorder indication 370143000
Suicidal thoughts contraindication 6471006
Bipolar disorder contraindication 13746004 DOID:3312
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Syndrome of inappropriate vasopressin secretion contraindication 55004003 DOID:3401
Blood coagulation disorder contraindication 64779008 DOID:1247
Hyponatremia contraindication 89627008
Seizure disorder contraindication 128613002
Suicidal contraindication 267073005
Serotonin syndrome contraindication 371089000




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.56 acidic
pKa2 13.13 acidic
pKa3 8.58 Basic
pKa4 1.41 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
20MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
40MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL Jan. 31, 2023 INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS AGES 7 TO 17 YEARS OF AGE WITH MAJOR DEPRESSIVE DISORDER
10MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY
20MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY
40MG VIIBRYD ABBVIE N022567 Jan. 21, 2011 RX TABLET ORAL July 31, 2023 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sodium-dependent serotonin transporter Transporter INHIBITOR IC50 9.30 IUPHAR CHEMBL
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 9.70 IUPHAR CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.41 CHEMBL
D(3) dopamine receptor GPCR AGONIST IC50 7.15 IUPHAR
Histamine H1 receptor GPCR AGONIST IC50 6.50 IUPHAR
Sodium-dependent dopamine transporter Transporter IC50 6.53 CHEMBL
5-hydroxytryptamine receptor 4 GPCR AGONIST IC50 6.60 IUPHAR
Adrenergic receptor alpha-2 GPCR IC50 5.22 CHEMBL
D(2) dopamine receptor GPCR AGONIST IC50 6.18 IUPHAR
Adrenergic receptor alpha-1 GPCR IC50 5.70 CHEMBL
Sodium-dependent noradrenaline transporter Transporter IC50 6.80 CHEMBL
5-hydroxytryptamine receptor 1B GPCR IC50 5.30 CHEMBL
D(2) dopamine receptor GPCR IC50 6.18 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 9.52 CHEMBL
Sodium-dependent serotonin transporter Transporter IC50 9.30 CHEMBL
5-hydroxytryptamine receptor 2A GPCR IC50 5.82 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
5-hydroxytryptamine receptor 7 GPCR IC50 5.52 CHEMBL
Acetylcholinesterase Enzyme IC50 4.67 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 5.70 CHEMBL
5-hydroxytryptamine receptor 4 GPCR IC50 6.60 CHEMBL
D(3) dopamine receptor GPCR IC50 7.15 CHEMBL
5-hydroxytryptamine receptor 1D GPCR IC50 5.40 CHEMBL
D(4) dopamine receptor GPCR IC50 5.47 CHEMBL
5-hydroxytryptamine receptor 6 GPCR IC50 5.52 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel IC50 5.37 CHEMBL

External reference:

IDSource
4030483 VUID
N0000182438 NUI
D09698 KEGG_DRUG
163521-08-2 SECONDARY_CAS_RN
4030483 VANDF
4030484 VANDF
C1530072 UMLSCUI
CHEBI:70707 CHEBI
CHEMBL439849 ChEMBL_ID
CHEMBL1615374 ChEMBL_ID
D000069503 MESH_DESCRIPTOR_UI
DB06684 DRUGBANK_ID
7427 IUPHAR_LIGAND_ID
7638 INN_ID
S239O2OOV3 UNII
6918314 PUBCHEM_CID
1086768 RXNORM
179494 MMSL
27744 MMSL
359491 MMSL
d07740 MMSL
013753 NDDF
013754 NDDF
702837008 SNOMEDCT_US
702838003 SNOMEDCT_US
715638004 SNOMEDCT_US
YG7 PDB_CHEM_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1110 TABLET 10 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1110 TABLET 10 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1120 TABLET 20 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1120 TABLET 20 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1140 TABLET 40 mg ORAL NDA 32 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 0456-1140 TABLET 40 mg ORAL NDA 32 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2043 TABLET, FILM COATED 40 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2044 TABLET, FILM COATED 20 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0480-2045 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-352 TABLET 10 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-352 TABLET 10 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-353 TABLET 20 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-353 TABLET 20 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-354 TABLET 40 mg ORAL ANDA 33 sections
Vilazodone Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 16729-354 TABLET 40 mg ORAL ANDA 33 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-232 TABLET, FILM COATED 10 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-233 TABLET, FILM COATED 20 mg ORAL ANDA 31 sections
VILAZODONE HYDROCHLORIDE Human Prescription Drug Label 1 46708-234 TABLET, FILM COATED 40 mg ORAL ANDA 31 sections
vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-691 TABLET 10 mg ORAL NDA authorized generic 31 sections
vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-691 TABLET 10 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-692 TABLET 20 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-692 TABLET 20 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-693 TABLET 40 mg ORAL NDA authorized generic 31 sections
Vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 51407-693 TABLET 40 mg ORAL NDA authorized generic 31 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4624 TABLET 40 mg ORAL NDA 29 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4624 TABLET 40 mg ORAL NDA 29 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4627 TABLET 20 mg ORAL NDA 29 sections
VIIBRYD HUMAN PRESCRIPTION DRUG LABEL 1 55154-4627 TABLET 20 mg ORAL NDA 29 sections
vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 60505-4772 TABLET 10 mg ORAL NDA authorized generic 31 sections
vilazodone HUMAN PRESCRIPTION DRUG LABEL 1 60505-4772 TABLET 10 mg ORAL NDA authorized generic 31 sections